Clinical Trial Update: LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1, double-blind, placebo-controlled study of LEO 22811 in healthy subjects completed, assessing safety and pharmacokinetics after single and multiple oral…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• LEO 22811

Snippet

Sponsor: LEO Pharma | Conditions: Psoriasis Vulgaris | Phase 1 | Status: COMPLETED